HEPATOBILIARY MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE: RAISING CONCERN ON AN OLD DILEMMA
DOI:
https://doi.org/10.22551/baq4gx22Abstract
Inflammatory bowel disease (IBD) is increasingly recognized as a multisystem disorder with significant extraintestinal manifestations, including hepatobiliary complications. This prospective study aimed to assess the prevalence of hepatic manifestations and associated risk factors in a real-world IBD cohort. Materials and methods: Between December 2023 and March 2024, 153 patients (78 with ulcerative colitis and 75 with Crohn’s disease) were enrolled at a tertiary care center in northeast Romania. Comprehensive clinical evaluations, laboratory assessments, abdominal ultrasound, and vibration-controlled transient elastography with controlled attenuation parameter (CAP) were performed. Results: Hepatobiliary abnormalities were identified in 43.1% of patients, with steatotic liver disease (SLD) being the most common manifestation (26.8%). Notably, SLD was observed in 30.8% of ulcerative colitis and 22.7% of Crohn’s disease patients. Patients with hepatic manifestations exhibited higher inflammatory markers (white blood cell count, C-reactive protein), liver enzymes, CAP values, and fibrosis, alongside longer disease duration and increased flare frequency. Multivariate analysis revealed that older age, higher body mass index, a diagnosis of Crohn’s disease, and elevated CRP levels were independent predictors of hepatic involvement. Conclusions: These findings underscore the importance of routine liver screening and integrated hepatologic assessment in IBD management to address potential complications and improve patient outcomes.
References
1. Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2023; 30(2): 230-239.
2. Veltkamp C, Lan S, Korompoki, E, et al. Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. J. Clin. Med 2022; 11: 2623.
3. Ritaccio G, Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, Wong U. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare. Dig Dis Sci 2021; 66(9): 3186-3191.
4. Chalasani N, Younossi Z, Lavine JE, et al The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
5. Núñez FP, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in in-flammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337.
6. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. Systematic review: The epidemiology of hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40(1): 3-15.
7. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45(5): 1267-1274.
8. Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifesta-tions and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res 2018; 11(2): 83-94.
9. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663.
10. Garcia-Cortes M, Robles-Diaz M, Stephens C, et al. Drug induced liver injury: an update. Arch Toxicol 2020; 94: 3381-3407.
11. D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol 2019; 12: 1756284819848631.
12. Núñez FP, Quera R, Bay C, Castro F, Mezzano G. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease J Crohns Colitis 2022; 16(7): 1168-1176.
13. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78(6): 1966-1986.
14. Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 2024; 59(2): 150-156
15. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int 2024; 44(8): 1762-1767.
16. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol 2024; 17: 374 - 443.
17. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifesta-tions of Inflammatory Bowel Disease. Inflamm Bowel Dis 2015; 21(8): 1982-1992.
18. Beheshti Maal A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, Mansournia MA, Vosough M. Prev-alence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Sys-tematic Review and Meta-Analysis of more than 1.7 Million Patients. J Crohns Colitis 2024; 18(3): 360-374.
19. Sartini A, et al. NAFLD in IBD: Prevalence and risk factors. J Gastroenterol Hepatol 2019; 34(10): 1789-1795.
20. Kim J, et al. MASLD in IBD patients: A prospective study. Clin Gastroenterol Hepatol 2023; 21(4): 987-994.
21. Gonzalez R, et al. Hepatic steatosis in CD vs. UC: A comparative study. Inflamm Bowel Dis 2020; 26(11): 1705-1712.
22. Martinez E, et al. Hepatobiliary complications in CD: A cohort study. J Crohns Colitis 2023; 17(5): 754-761.
23. Silva T, et al. Metabolic liver changes in CD patients. Dig Liver Dis 2019; 51(8): 1123-1129.
24. Chen Y, et al. Disease duration and NAFLD in IBD: A systematic review. Dig Dis Sci 2022; 67(10): 4902-4910.
25. Torres J, et al. MASLD and clinical outcomes in IBD: A meta-analysis. J Hepatol 2022; 77(3): 789-798.
26. Patel S, et al. Inflammation and NAFLD progression in IBD. Gut 2021; 70(11): 2104-2112.
27. Unger LW, Forstner B, Muckenhuber M, et al. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Dig Dis Sci 2020; 65(9): 2712-2718 / doi:10.1007/s10620-019-06000-y.
28. Capela TL, Silva VM, Freitas M, et al. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores. BMC Gastroenterol 2023; 23(1): 437 / doi:10.1186/s12876-023-02988-w.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 The Medical-Surgical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
